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Abstract. 
 
We describe a key role for the CD44 trans-
membrane glycoprotein in Schwann cell–neuron inter-
actions. CD44 proteins have been implicated in cell ad-
hesion and in the presentation of growth factors to high 
afﬁnity receptors. We observed high CD44 expression 
in early rat neonatal nerves at times when Schwann 
cells proliferate but low expression in adult nerves, 
where CD44 was found in some nonmyelinating 
Schwann cells and to varying extents in some myelinat-
ing ﬁbers. CD44 constitutively associated with erbB2 
and erbB3, receptor tyrosine kinases that heterodimer-
ize and signal in Schwann cells in response to neuregu-
lins. Moreover, CD44 signiﬁcantly enhanced neuregu-
lin-induced erbB2 phosphorylation and erbB2–erbB3 
heterodimerization. Reduction of CD44 expression in 
vitro resulted in loss of Schwann cell–neurite adhesion 
and Schwann cell apoptosis. CD44 is therefore crucial 
for maintaining neuron–Schwann cell interactions at 
least partly by facilitating neuregulin-induced erbB2–
erbB3 activation.
Key words: CD44 • erbB2 • erbB3 • Schwann cell • 
neuregulin
 
Introduction
 
Schwann cells are neural crest derivatives that ensheathe
and myelinate axons of peripheral nerves (for review see
Bunge and Fernandez-Valle, 1995; Jessen and Mirsky, 1998).
Migrating Schwann cell precursors enter nerves after
growth cones of axons have begun to extend towards their
targets (Carpenter and Hollyday, 1992; Bhattacharyya et al.,
1994). The timing of Schwann cell differentiation and the
ratio of Schwann cells to neurons must be strictly con-
trolled as peripheral nerves develop. Schwann cells prolif-
erate until early postnatal development, then either be-
come quiescent (Brown and Asbury, 1981; Stewart et al.,
1993) or undergo apoptosis (Grinspan et al., 1996; Syroid
et al., 1996; Nakao et al.
 
, 
 
1997; Zorick et al., 1999). Signals
that influence developing Schwann cell proliferation, dif-
ferentiation, and survival are derived from axons (Bunge
and Fernandez-Valle, 1995; Jessen and Mirsky, 1998). Elu-
cidating the molecular mechanisms governing Schwann
cell responses to these axon-derived signals is crucial for
understanding how nerves develop.
Axon-derived signals that influence Schwann cell prolif-
eration and survival include members of the neuregulin
protein family (for review see Mirsky and Jessen, 1999;
Topilko et al., 1996). Neuregulins are encoded by alterna-
tively spliced transcripts of the neuregulin-1 (
 
NRG-1
 
)
gene (Burden and Yarden, 1997; for review see Gassmann
and Lemke, 1997). Neuregulins, including glial growth fac-
tors (GGFs),
 
1
 
 are either membrane bound or soluble, each
with domains homologous to epidermal growth factor
(EGF). Mice with targeted 
 
NRG-1
 
 deletions have dramat-
ically reduced numbers of Schwann cell precursors (Meyer
and Birchmeier, 1995). In vitro, neuregulin blocking anti-
bodies inhibit the mitogenic effects of dorsal root ganglion
(DRG) neurons on Schwann cells (Levi et al., 1995; Mor-
rissey et al., 1995; Rosenbaum et al., 1997), while GGF
and other neuregulins promote mitogenesis of mature
Schwann cells and Schwann cell precursors (Baek and
Kim, 1998; Raff et al., 1978; Marchionni et al., 1993; Dong
et al., 1995). In addition, neuregulins can rescue Schwann
cell precursors (Dong et al., 1995; Syroid et al., 1996) and
Schwann cells in damaged neonatal nerves (Trachtenberg
and Thompson, 1996; Grinspan et al., 1996; Kopp et al.,
1997) from apoptosis. Collectively, these data indicate that
neuregulins are critical for Schwann cell differentiation,
survival, and proliferation at different stages of peripheral
nerve development.
 
In Schwann cells, neuregulins function through the trans-
membrane receptor tyrosine kinases erbB2 and erbB3
(Morrissey et al., 1995; Vartanian et al., 1997; Rahmatul-
lah et al., 1998). Mice with targeted mutations at 
 
erb
 
B2 or
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erb
 
B3 lack Schwann cells, underscoring the importance of
these receptors in peripheral nerve development (Rieth-
macher et al., 1997; Britsch et al., 1998; Morris et al., 1999).
Although erbB2 has no known ligands, neuregulins bind
erbB3 with varying affinities (Peles et al., 1993; Carraway
and Cantley, 1994; Kita et al., 1994). However, erbB3 lacks
intrinsic kinase activity (Guy et al., 1994). After ligand
binding, erbB3 and erbB2 must heterodimerize in order to
signal (Sliwkowski et al., 1994). It is unclear from these stud-
ies how erbB2–erbB3 heterodimerization is achieved. Fur-
thermore, it is not known whether neuregulins reach
erbB2 and erbB3 by simple diffusion, or if accessory pro-
teins are required to sequester neuregulins to the Schwann
cell membrane.
We have investigated the possibility that CD44 plays a
role in mediating neuregulin signaling in the peripheral
nervous system. The CD44 family of transmembrane gly-
coproteins has been implicated in cell–cell and cell–matrix
adhesion, cell migration, and growth factor signaling (for
review see Sherman et al., 1996; Naor et al., 1997). Differ-
ent CD44 proteins are generated from a single gene by al-
ternative RNA splicing of up to 10 variant (“v”) exons and
by extensive posttranslational modifications. These vari-
ant exons encode amino acid sequences in the extracellu-
lar portion of CD44, near the transmembrane domain
(Screaton et al., 1992). Standard CD44 is an 85–90-kD pro-
tein that lacks variant sequences and is expressed in many
cell types, whereas higher molecular weight variants are
expressed in a limited number of tissues and in certain tu-
mors. CD44 is expressed by subpopulations of rat neural
crest cells (Ikeda et al., 1996) and by embryonic and neo-
natal rat (embryonic day [E]18 to postnatal day [P]2; Sher-
man et al., 1995) and adult human Schwann cells (Vogel
et al., 1992; Sherman et al., 1997). However, the function
of CD44 in the peripheral nervous system has not been
studied.
Bourguignon et al. (1997) found that CD44 coimmuno-
precipitated with erbB2 in an ovarian carcinoma cell line,
suggesting that CD44 may be linked to erbB2 signaling.
We investigated whether CD44 contributes to erbB2 and
erbB3 function in Schwann cells. We found that CD44 as-
sociates with erbB2 and erbB3 in rat Schwann cells and
that reducing CD44 expression prevents GGF-induced
erbB2–erbB3 heterodimerization and signaling. Blocking
CD44 expression also results in the release of Schwann
cells from neurites in cocultures of Schwann cells and sen-
sory neurons, and in Schwann cell apoptosis. These data
indicate that CD44 facilitates neuregulin signaling in
Schwann cells, and demonstrate a novel role for CD44 in
mediating growth factor receptor function.
 
Materials and Methods
 
Reagents
 
Recombinant human GGF2 was provided by Mark Marchionni (Cam-
bridge Neuroscience, Cambridge, MA). Tyrphostin AG825 was pur-
chased from Calbiochem. Antisense (AS1: 5
 
9
 
-GAAAAGGGTCGC-
GGGGG-3
 
9
 
, see Lamb et al., 1997; AS2: 5
 
9
 
-CTTGTCCATGATGTGCA-
3
 
9
 
) and scrambled control antisense (SAS1: 5
 
9
 
-GGAGAGAGAGGCG-
GCT-3
 
9
 
; SAS2: 5
 
9
 
-ACCTGTTGGTTCACGAT-3
 
9
 
) CD44 phosphoro-
thioate-protected oligonucleotides were synthesized at the University of
Cincinnati DNA Core Facility.
 
Schwann Cell Culture
 
Primary Schwann cell cultures were established from neonatal Sprague-
Dawley rat (Harlan) sciatic nerves as previously described (Kim et al.,
1997). Cells were initially grown on poly-
 
L
 
-lysine–coated (Sigma-Aldrich)
tissue culture plastic in DMEM supplemented with 10% FBS, 5 ng/ml re-
combinant human (rh)-GGF2, and 2 
 
m
 
M forskolin (Calbiochem-Novabio-
chem), and then either seeded onto neurons (see below) or switched for
24 h to a serum-free defined medium (N2; see Kleitman et al., 1991) either
with or without rh-GGF2 and oligonucleotides as described. All assays
were performed on cultures at passage 2 or 3. Apoptosis assays were per-
formed using a Tdt-FragEL DNA fragmentation detection kit (Oncogene
Research Products) according to the manufacturer’s instructions.
 
Schwann Cell–Neuron Cocultures
 
Dissociated rat E15 DRG were cultured on collagen-coated 8-well cham-
ber slides (Fisher Scientific) in the presence of antimitotic drugs to kill di-
viding cells (Kleitman et al., 1991). Neurons were maintained in DMEM
plus 10% human placental serum and 50 ng/ml 2.5 S NGF (Harlan) for 14 d.
Approximately 10
 
5
 
 primary rat Schwann cells were then seeded onto the
established neurons. 2 d later, cultures were analyzed by microscopy to
confirm that the seeded cells preferentially bound to neurites. Cultures
were then treated with AS or SAS oligonucleotides, then examined every
24 h by phase–contrast microscopy. In a separate set of experiments,
Schwann cells were pretreated with AS or SAS CD44 oligonucleotides
and then plated onto neurons, as described. In each culture, 
 
.
 
50 micro-
scopic fields of neurites were examined at each time point.
 
Immunocytochemistry and Laser Confocal Microscopy
 
For studies of nerve sections, sciatic nerves were dissected from Sprague-
Dawley rat pups (P1, P3, P5, and P7; Harlan) and adults that had been
perfused with 4% paraformaldehyde (in 0.1 M phosphate buffer). Nerves
were post-fixed overnight and then incubated in 20% sucrose for 24 h.
Frozen 5-
 
m
 
m sections were cut on a cryostat (Carl Zeiss, Inc.), fixed again
in paraformaldehyde for 10 min, rinsed in phosphate buffer, and then in-
cubated with 0.5% hydrogen peroxide to block endogenous peroxidases.
Sections were blocked in 10% normal goat serum in phosphate buffer for
1 h, then incubated with the mouse anti–rat CD44 monoclonal antibody
5G8 (total hybridoma supernatant) overnight at room temperature (Slee-
man et al., 1996). Slides were then developed using either the Vectastain
ABC immunocytochemistry kit according to the manufacturer’s instruc-
tions (Vector Laboratories) or by incubation with FITC-conjugated goat
anti–mouse IgG (1:100; Jackson Immunoresearch Laboratories). Sections
then either were rinsed three times with buffer and mounted in Fluoro-
mount G (EM Sciences) or were processed further. For double labeling,
CD44 antibody-labeled sections were fixed again with paraformaldehyde,
rinsed, permeabilized in 0.1% Triton X-100 for 15 min, blocked in 10%
goat serum for 1 h, and then incubated with rabbit antineurofilament (1:
50; Parysek and Goldman, 1987; provided by Linda Parysek, University of
Cincinnati), rabbit anti-S100 (1:200; Dako), rabbit anti-erbB2 (1:10; Up-
state Biotechnology), or rabbit anti-erbB3 (1:10; C-17; Santa Cruz Bio-
technology) antibodies overnight. Next, sections were rinsed, incubated
with goat anti–rabbit TRITC (1:100; Jackson Immunoresearch Laborato-
ries) for 1 h, and mounted as above. Sections were analyzed either with a
Zeiss Axiophot microscope (Carl Zeiss, Inc.) with epifluorescence or by
confocal microscopy using a Zeiss LM-10 (Carl Zeiss, Inc.) or a Bio-Rad
MRC-600 laser confocal microscope (Bio-Rad Laboratories).
For analysis of teased nerves, adult rats were killed and sciatic nerves
were removed and placed into L15 medium. Nerves were cut to 0.55-mm
lengths and teased to single fibers using 20-gauge needles in PBS, then
dried onto gelatin-coated glass slides. Slides were stored at 
 
2
 
80
 
8
 
C until
used. For immunostaining, slides were warmed to room temperature,
fixed in methanol at 
 
2
 
20
 
8
 
C for 10 min, rinsed in PBS, and blocked in 10%
normal goat serum for 1 h. Sections were incubated with mouse mono-
clonal anti-CD44 (5G8) at a 1:1 dilution overnight, rinsed, and incubated
with goat anti–mouse FITC (1:100) for 1 h, then rinsed again. For double
labeling with S-100 protein, nerves immunostained with the CD44 anti-
body were fixed in 4% paraformaldehyde, rinsed, permeabilized in Triton
X-100, and blocked in normal goat serum. Nerves were then incubated in
S-100 antibody (Dako) overnight, rinsed, incubated with goat anti–rabbit
TRITC (1:100) for 1 h, rinsed again, and mounted in fluoromount G and
analyzed as described above. 
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For immunocytochemical localization of CD44, erbB2, and erbB3 in
cultured Schwann cells, primary rat Schwann cells were plated onto poly-
 
L
 
-lysine–coated 8-well chamber slides (Fisher Scientific) and fixed with
4% paraformaldehyde in PBS for 20 min at room temperature. Cells were
permeabilized and blocked by incubation in PBS with 10% normal goat
serum and 0.2% Triton X-100 for 30 min. Cells were then incubated with a
mixture of the anti-CD44 mouse monoclonal antibody 5G8 (1:50) and ei-
ther anti-erbB2 rabbit polyclonal antibody (1:100) or anti-erbB3 rabbit
polyclonal antibody (1:100) as above for 1 h at room temperature. Next,
cells were washed three times with blocking buffer and incubated for 30
min with a 1:50 dilution of FITC-conjugated goat anti–mouse IgG and a
1:50 dilution of rhodamine-conjugated goat anti–rabbit IgG (Jackson Im-
munoresearch Laboratories). Labeled cells were washed three times with
blocking buffer and then mounted in Fluoromount G (EM Sciences).
Cells were viewed and photographed as above.
 
Coimmunoprecipitation and Western Blotting
 
Cells were washed twice with ice-cold PBS and lysed in 50 mM Tris-HCl
(pH 7.4), 150 mM NaCl, and 1% Triton X-100 buffer with 0.5 mM phenyl-
methylsulfonyl fluoride, 1 
 
m
 
g/ml each of aprotinin, leupeptin, and pep-
statin, 50 mM NaF, and 1 mM sodium orthovanadate (all obtained from
Sigma-Aldrich). Cellular debris was pelleted by centrifugation at 10,000
rpm for 10 min, then lysates were incubated overnight at 4
 
8
 
C with 5 
 
m
 
g/ml
of anti-erbB2 (Upstate Biotechnology or Oncogene Research Products,
Ab-4), anti-erbB3 (Santa Cruz Biotechnology, Inc.), or anti-CD44 anti-
bodies (as described above), or isotype-matched control Igs (Jackson Im-
munoresearch Laboratories). By Western blotting, we observed only sin-
gle bands at 185 kD with these erbB antibodies. Protein complexes were
immunoprecipitated by adding a 50% slurry of protein A–Sepharose
(Amersham Pharmacia Biotech), equilibrated in lysis buffer, for 1 h.
Beads were washed four times in lysis buffer, then incubated with Laem-
mli buffer at 95
 
8
 
C for 10 min.
For Western blotting, proteins were separated on 7% SDS-PAGE gels,
blotted onto nitrocellulose, then blocked in PBS with 0.1% Tween 20 and
3% nonfat dry milk for 1 h. Blots were incubated with 5G8 (1:250), anti-
erbB2 (1:1,000), or anti-erbB3 (1:1,000) antibodies in blocking buffer,
washed three times, then incubated with HRP-conjugated goat anti–
mouse or anti–rabbit IgG antibodies (1:2,500; Bio-Rad Laboratories).
Blots were washed an additional three times in blocking buffer, then de-
veloped using enhanced chemiluminescence (ECL)
 
1
 
 (Amersham Phar-
macia Biotech). For assays of phosphorylated erbB2, the antiphospho
erbB2 antibody (Upstate Biotechnology) was used at 1:1,000.
 
Results
 
CD44 Expression Decreases with Age during Postnatal 
Peripheral Nerve Development
 
As an initial test of our hypothesis that CD44 plays a role
in peripheral nerve development and function, we ana-
lyzed CD44 distribution in developing and adult rat sciatic
nerves. We previously demonstrated that CD44 is present
in embryonic and adult nerves (Sherman et al., 1995, 1997),
but relative levels of expression and detailed localization
were not defined. Cryostat sections of rat sciatic nerve
were stained with a monoclonal antibody raised against
the extracellular domain of CD44 (5G8). This antibody
recognizes all forms of CD44, but not other proteins, by
Western blotting, immunoprecipitation, and immunohis-
tochemistry (Sleeman et al., 1996). Nerves from P3 ani-
mals showed robust staining. CD44 expression was de-
tected in axon–Schwann cell bundles, in endoneurium, and
in the perineurium (Fig. 1 A). In adult nerves, however,
staining was greatly reduced both in nerve bundles (Fig. 1
B) and in perineurium (data not shown). In a second set of
experiments, we stained paraffin sections of P1, P3, P5,
and P7 nerves. Strong staining persisted through P5 but
was diminished by P7, and, as above, was very low in adult
nerves (data not shown). This pattern of expression is con-
sistent with CD44 playing a role in Schwann cell prolifera-
tion and/or differentiation.
 
CD44 Colocalizes with erbB2 and erbB3 in
Schwann Cells
 
Like CD44, erbB2 expression is high during perinatal
Schwann cell proliferation and much lower as Schwann
cells become quiescent during the postnatal period and in
adult animals (Cohen et al., 1992; Jin et al., 1993; Carroll
et al., 1997). To test whether CD44 and erbB2 or erbB3
colocalize in peripheral nerve tissue, we examined cryostat
sections of P3 and adult rat sciatic nerves by double label-
ing immunohistochemistry with anti-CD44 and anti-erbB2
antibodies using laser confocal microscopy. In P3 nerves,
perineurial cells expressed CD44 but not erbB2 (Fig. 2,
top left). Some domains of axon–Schwann cell bundles ex-
pressed both erbB2 and CD44, whereas other domains
were positive for one but not both proteins (Fig. 2, top
left). Sections stained with anti-erbB3 and anti-CD44 anti-
bodies gave identical results (data not shown). P3 nerve
sections were also double labeled with antibodies recog-
nizing CD44 and S100 protein to mark Schwann cells (Fig.
2, top right) or neurofilament to mark axons (Fig. 2, top
center). Both neurofilament and S100 protein demon-
strated patchy expression within axon bundles but the de-
gree of colocalization with CD44 was significantly less
than with erbB2. These data are consistent with CD44 be-
ing expressed at P3 in some Schwann cell membrane do-
mains that contain erbB2 and erbB3.
Double labeling of adult sciatic nerve cross-sections
with CD44 and erbB2 antibodies revealed patches where
the two proteins colocalized (Fig. 2, middle left). Consis-
Figure 1. CD44 expression is high in early postnatal peripheral
nerve and decreases in adult nerve. Neonatal (P3; left) or adult
(right) rat sciatic nerves were cryosectioned and immunolabeled
with an antibody (5G8) that recognizes all forms of CD44. In P3
nerves, CD44 expression was high in the perineurial cells (PN)
and throughout nerve bundles (*). In adult nerves, however,
CD44 expression was dramatically reduced, with only occasional
bright staining within nerve bundles and by endothelial cells of
blood vessels (BV). Note that both of the above panels had iden-
tical exposure and printing times to allow for direct comparisons
of signal intensity. Bar, 10 mm. 
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Figure 2. CD44 expression as compared with erbB2, neurofilament, and S-100 protein in peripheral nerve. Cryostat sections of P3 (top
row) and adult (middle row) rat sciatic nerves were labeled with the 5G8 mouse anti–rat CD44 antibody (followed by an FITC-conju-
gated secondary antibody; green) and anti-erbB2, anti-neurofilament M1H (NF) or anti-S100 protein antibodies (followed by a
rhodamine-conjugated secondary antibody; each in red), then analyzed by laser confocal microscopy. CD44 was expressed in the
perineurium (upper left of each panel in top row), in blood vessels (data not shown), and in many regions of axon–Schwann cell bundles
in P3 nerves. CD44 overlapped extensively with erbB2 in P3 nerve (*, yellow, top left), but less so with neurofilament or S100 protein.
In adult nerves, CD44 was much more weakly expressed (see Fig. 1), as was erbB2. The center row shows enhanced signals as compared
with the top row, so that staining can be easily visualized. Some CD44 colocalization with erbB2 was evident in probable unmyelinated
fiber bundles (middle left, arrows) and at the outer part of some Schwann cell abaxonal surfaces. CD44 did not colocalize with neurofil-
ament protein, a marker of axons. Very little colocalization of CD44 with S100 protein was noted except outside a few myelin sheaths
(middle right, arrowheads). Arrows denote probable examples of unmyelinated fiber bundles. The bottom row shows photographs of
adult rat teased nerve preparations stained with designated antibodies. Shown at the lower left, anti-S100 marked thin unmyelinated fi-
bers (arrows and arrowhead) and thicker myelinated fibers (asterisks). Anti-CD44 labeling of the same field shows expression in one
unmyelinated fiber (arrows) but not another (arrowhead). Myelinated fibers show weak labeling by anti-CD44. In the bottom right, rare
myelinated fibers with bright anti-CD44 labeling at the abaxonal Schwann cell surface are shown (arrow) with adjacent lightly labeled fi-
bers (arrowhead). Bar: (top six panels) 10 mm; (bottom three panels) 69.4 mm. 
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tent with findings in teased nerves (see below), most
patches of CD44-erbB2 colocalization are probably unmy-
elinated Schwann cell bundles. There was also colocaliza-
tion of CD44 and erbB2 in the abaxonal Schwann cell
membrane, but only in some myelinated fibers. CD44 but
not erbB2 expression was in rings outside myelin sheaths.
This CD44 may be in the abaxonal Schwann cell mem-
brane and/or the endoneurium. Finding CD44 in the endo-
neurium would be consistent with previous studies show-
ing that, under certain circumstances, CD44 can be shed
from cell membranes (Gunthert et al., 1996). Electron mi-
croscopy will be necessary to determine if this CD44 is lo-
calized to one or both of these compartments.
Double labeling with erbB2 and CD44 antibodies sug-
gested that much of the CD44 expression in adult periph-
eral nerves could be ascribed to Schwann cells. Indeed, in
adult nerve cross-sections, CD44 did not colocalize with
neurofilament (Fig. 2, middle). However, expression of the
Schwann cell marker S100 protein only partially over-
lapped with CD44 expression (Fig. 2, middle right). To
clarify the distribution of CD44 and S100 protein in adult
nerves, individual teased adult sciatic nerve fibers were
double labeled with antibodies against S100 protein and
CD44. CD44 was easily detected in the outer, abaxonal
membrane of a few brightly stained myelinated fibers (2
out of 40 counted; Fig. 2, bottom right). A larger percent-
age of myelinated fibers (38 out of 40) only weakly ex-
pressed CD44 (Fig. 2, bottom middle). As anticipated by
the staining in cross-sections, S100 protein was predomi-
nantly detected in the adaxonal, inner cytoplasm and much
less in the abaxonal Schwann cell surface where CD44 was
found.
Although S100 protein is barely detectable in unmyelin-
ating Schwann cells in cross-sections (Mata et al., 1990; see
Fig. 2, middle right), anti-S100 antibodies did stain un-
myelinated fibers in teased nerve preparations (Fig. 2, bot-
tom left). Only some of these unmyelinated fibers ex-
pressed CD44 (11 out of 45; Fig. 2, bottom middle). These
data demonstrate that subsets of both myelinating and un-
myelinating Schwann cells express detectable levels of
CD44 in adult nerve.
These studies confirm that CD44 is present in peripheral
nerves and demonstrate that it is enriched in developing
nerves. The data are consistent with colocalization of
CD44 with erbB2 and/or erbB3 in specific membrane do-
mains of Schwann cells. To confirm this, cultures contain-
ing 
 
.
 
99% S100
 
1
 
 neonatal rat Schwann cells were pre-
pared and stained with anti-CD44 and anti-erbB2 (Fig. 3)
or erbB3 (data not shown) antibodies. Indeed, patches of
membrane showed colocalization of the receptors with
CD44, while adjacent membrane domains appeared to be
enriched for either CD44 or erbB receptors (Fig. 3 C).
 
CD44 Associates with erbB2 and erbB3
 
In combination with the observation that CD44 associates
with erbB2 in ovarian carcinoma cells (Bourguignon et al.,
1997), the finding that erbB2 and erbB3 colocalize with
CD44 in Schwann cells suggested that CD44 may play a
role in erbB receptor function. To determine whether CD44
associates with either erbB2 or erbB3, we cultured rat
Schwann cells in a defined medium in the absence of
added growth factors for 24 h. Cells were then treated for
5 min with 5 ng/ml of rh-GGF2, a neuregulin previously
shown to promote Schwann cell precursor survival and
Schwann cell proliferation (Minghetti et al., 1996), or with
an equivalent volume of vehicle (culture medium). Cell
lysates were immunoprecipitated with either erbB2 or
erbB3 antibodies and were analyzed by Western blotting.
We found that CD44 coimmunoprecipitated with erbB2
and, in apparently distinct complexes, with erbB3 in the
absence of rh-GGF2, indicating that CD44 constitutively
Figure 3. CD44 partially colocalizes with erbB2 in Schwann cells in vitro. Primary rat Schwann cells were fixed and immunostained with
the anti-CD44 mouse monoclonal antibody 5G8 and an anti-erbB2 polyclonal antibody. (A and E) Phase–contrast images of single
Schwann cells. (B) CD44 staining detected with FITC-conjugated goat anti–mouse IgG. (C) erbB2 staining detected with rhodamine-
conjugated goat anti–rabbit IgG. (D) Merged images from B and C, showing where there is extensive overlapping CD44 and erbB2 ex-
pression (yellow; arrowhead) and where there is little if any colocalization (arrows). Control labeling using the Schwann cell shown in E
included incubation with both secondary antibodies alone (F), incubation with the 5G8 monoclonal antibody followed by the goat anti–
rabbit secondary (G), and incubation with the erbB2 polyclonal antibody followed by the goat anti–mouse secondary antibody (H). 
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associates with each receptor (Fig. 4). This association did
not depend on erbB2–erbB3 activation, since there was lit-
tle erbB2–erbB3 heterodimerization under these condi-
tions (Fig. 4) and because CD44–erbB interactions were
not disrupted by treating cells with 10 
 
m
 
M tyrphostin
AG825, a pharmacological inhibitor of erbB2 phosphory-
lation (data not shown). Less than 10% of total erbB3 im-
munoprecipitated with erbB2 in the absence of rh-GGF2
(as determined by scanning densitometry, comparing
Westerns blots of total cell lysates to immunoprecipitates),
whereas 
 
.
 
40% immunoprecipitated in the presence of rh-
GGF2 (
 
n
 
 5 
 
3). The low level of heterodimerization in un-
treated cultures may be the result of autocrine activation
of erbB2 and erbB3 by Schwann cell–derived neuregulins,
as previously described (Rosenbaum et al., 1997). CD44–
erbB2 and CD44–erbB3 interactions were also observed
when cell lysates were immunoprecipitated with CD44 an-
tibodies (data not shown). In the presence of rh-GGF2,
CD44, erbB2, and erbB3 were all coimmunoprecipitated
(Fig. 4), indicating that CD44 remains associated with
erbB2 and erbB3 in neuregulin-induced erbB2–erbB3 het-
erodimers. The level of CD44 in the heterodimeric com-
plexes was approximately twice as high as the levels ob-
served in the absence of rh-GGF2, even though the total
levels of CD44 were not significantly changed in the cell
lysates. These data are consistent with the notion that rh-
GGF2 induces the formation of CD44–erbB2–CD44–
erbB3 complexes in Schwann cells.
 
Antisense CD44 Oligonucleotides Inhibit Schwann 
Cell–Neurite Adhesion in Schwann Cell–Sensory 
Neuron Cocultures
 
To address the possible functions of CD44 in peripheral
nerves, we analyzed Schwann cell–sensory neuron cocul-
tures that can be used to study how Schwann cells interact
with axons (Salzer and Bunge, 1980; Kleitman et al., 1991).
To reduce Schwann cell CD44 expression, we used previ-
ously described antisense CD44 oligonucleotides that ef-
fectively reduce total CD44 protein levels in rat cells
(Lamb et al., 1997). We chose this approach because there
are no antibodies that block all of the functions of the
CD44 proteins expressed by rat Schwann cells, and be-
cause antisense strategies have been used extensively to
block CD44 expression in numerous systems in vitro and
in vivo (Merzak et al., 1994; Kaya et al., 1997, 1999; Lamb
et al., 1997; Chow et al., 1998; Reeder et al., 1998). After
24 h, Schwann cell cultures treated with 5 
 
m
 
M of either of
two phosphorothioate-protected antisense CD44 oligonu-
cleotides (AS1 or AS2) expressed 40–70% less CD44 pro-
tein (range in seven separate experiments as determined
by scanning densitometry of Western blots) than did cells
treated with the same concentration of a oligonucleotides
with the identical base composition in a random sequence
(SAS1 or SAS2; Fig. 5 A; see also Fig. 8 A) or untreated
controls. In contrast, erbB3 demonstrated no detectable
changes in expression after 24 h and minimal (20–30% us-
ing AS1; range in three separate experiments) or no reduc-
tion (using AS2) in expression after 36 h (Fig. 5 A). This
minimal reduction is consistent with the increased level of
cell death observed in CD44 AS-treated cultures (see be-
low).
Having determined that the AS CD44 oligonucleotide
effectively reduced CD44 expression in Schwann cells, we
examined the effects of antisense CD44 on Schwann cell–
neuron interactions. Cultures of E16 rat DRG neurons,
from which endogenous Schwann cells and fibroblasts had
been removed with antimitotic drugs, were seeded with
Schwann cells. By 48 h, Schwann cells aligned with and
covered the majority of neurites. Cultures were then
treated with either SAS or AS CD44 oligonucleotides as
above. Schwann cells remained associated with neurites in
SAS-treated cultures (Fig. 5 B, arrows), but lost adhesion
to neurites in AS CD44–treated cultures within 48 h (Fig. 5
C). Clumps of dead cells were observed floating in these
cultures (Fig. 5 C). If Schwann cells were pretreated with
AS CD44 for 24 h and then added to neuron cultures, they
failed to adhere to neurites and died soon after seeding
(data not shown). These experiments were repeated three
times with similar results and suggest that CD44 is re-
quired to maintain Schwann cell–axon adhesion.
 
Reducing CD44 Expression in Schwann Cell Cultures 
Results in Apoptosis
 
We next tested the effects of antisense CD44 oligonu-
cleotides on purified cultures of primary rat Schwann
cells grown in the presence of 5 ng/ml rh-GGF2. After
Figure 4. CD44 associates with erbB2 and erbB3. erbB2 and erbB3
protein complexes were immunoprecipitated from subconfluent
100-mm plates of Schwann cells in the presence and absence of
rh-GGF2, then analyzed by Western blotting. Lys, aliquot of cell
lysate to control for changes protein levels; c, immunoprecipita-
tion with isotype-matched control antibody; ip, immunoprecipita-
tion with erbB2 or erbB3 antibody, as indicated; Probe, antibody
used in Western blots. Molecular weights were determined using
prestained markers (Bio-Rad Laboratories), and are shown on the
right. erbB2 and erbB3 each constitutively associated with CD44
in the absence of rh-GGF2, but only weakly with one another. In
the presence of rh-GGF2, erbB2 coimmunoprecipitated with erbB3
and approximately twice as much CD44 (as determined by scan-
ning densitometry) compared with untreated Schwann cells, even
though the total level of CD44 did not change (compare levels of
lysates in both conditions). Lanes containing lysates were equally
loaded with 10 mg of total protein. 
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48 h, 94 
 
6 
 
5% (as determined by cell counts) of Schwann
cells treated with the AS1 CD44 oligonucleotide became
rounded, lifted off the culture dish, and died (Fig. 6 C).
SAS1 oligonucleotide–treated and untreated control cul-
tures grew to confluence during the same time period (Fig.
6, A and B). Similar results were obtained using the AS2
and SAS2 oligonucleotides (Fig. 6, A–C, insets). After 36 h,
many cells grown in the presence of the AS1 CD44 oligo-
nucleotide were still attached to the culture substrate, but
20–30% (range of three separate experiments) of the cells
were undergoing apoptosis as determined by a nuclear
fragmentation assay (Fig. 7). These findings are consistent
with the notion that CD44 plays a crucial role in promot-
ing Schwann cell survival.
 
Excess rh-GGF2 Rescues Schwann Cells with Low 
CD44 Expression from Apoptosis
 
The finding that reducing CD44 expression leads to
 
Schwann cell apoptosis in purified Schwann cell cultures
suggests that CD44 is involved in mediating signals that
promote Schwann cell survival. As mentioned above, rh-
GGF2 is the chief added factor that can promote Schwann
cell survival in our cell culture system. If CD44 is involved
in promoting signaling by GGF or other neuregulins, then
one might expect that the effects of lowering CD44 ex-
pression by Schwann cells could be overcome by adding
high concentrations of such survival factors. When Schwann
cells were cultured in the presence of a 10-fold excess of
rh-GGF2 (50 ng/ml) and treated with AS1 CD44, we ob-
served significantly less cell death after 48 h (42
 
 
 
6 
 
12%;
Fig. 6, D–F) compared with cultures treated with only 5
ng/ml rh-GGF2 (Fig. 6 C). These data are consistent with
the idea that CD44 is involved in facilitating neuregulin
signaling.
 
Reducing CD44 Expression Inhibits erbB2 
Phosphorylation in Schwann Cells
 
To test directly whether reducing CD44 expression influ-
ences erbB2–erbB3 signaling, we cultured Schwann cells
in the presence of 5 ng/ml rh-GGF2 and either AS CD44
or SAS oligonucleotides for 24 h. 20 
 
m
 
g of protein from
each condition were examined for levels of erbB2 phos-
phorylation by Western blotting with a phospho-specific
erbB2 antibody. As expected, we observed a high level of
phosphorylated erbB2 in cultures treated with 5 
 
m
 
M SAS
oligonucleotides after GGF addition (Fig. 8 A). However,
there was a dose-dependent decrease in erbB2 phosphory-
lation in cells treated with increasing concentrations (from
1 to 5
 
m
 
M) of AS CD44 oligonucleotides, such that phos-
phorylation was barely detectable in cells treated with 5 
 
m
 
M
AS CD44 (the same concentration used in the experi-
ments described above). The levels of total erbB2 were ei-
ther unchanged in these experiments (using AS2) or re-
duced by 
 
z
 
20–30% (using AS1; range in three separate
experiments), as shown above for erbB3 (Fig. 5). As above,
we believe that this reduction probably is due to the fact
that a significant proportion of the Schwann cells are al-
ready undergoing apoptosis at this time point (Fig. 7).
Nonetheless, the degree of reduction in phosphorylation is
far greater (55–78%, range in three separate experiments)
than the reduction in total erbB2 protein. These data sug-
gest that CD44 is involved in signaling by erbB2–erbB3 re-
ceptor complexes in Schwann cells.
 
Reducing CD44 Expression Blocks erbB2–erbB3 
Heterodimerization in Schwann Cells
 
In light of our finding that CD44 forms complexes with
erbB2 and with erbB3, the observation that lowering
CD44 expression blocks erbB2 phosphorylation suggested
that CD44 might be required for efficient erbB2–erbB3
heterodimerization. To test this idea, we grew Schwann
cells in defined medium (N2) alone with either SAS1 or
AS1 CD44 oligonucleotides for 24 h, as above. Cells were
then treated with 5 ng/ml rh-GGF2 for 30 min and assayed
for erbB2–erbB3 heterodimerization by immunoprecipita-
tion with an erbB2 antibody, followed by Western blotting
with an erbB3 antibody. erbB3 coimmunoprecipitated
with erbB2 in SAS1 oligonucleotide–treated cultures, but
either barely or not at all in AS1 CD44–treated cultures
Figure 5. CD44 is required for Schwann cell–neurite adhesion in
vitro. (A) Primary cultures of rat Schwann cells were incubated
with 5 mM antisense (AS1 and AS2) CD44 or scrambled anti-
sense (SAS1 and SAS2) oligonucleotides, or left untreated (Ctrl)
for 24 h. Cultures were then lysed and 20 mg of total protein was
assayed for CD44 expression by Western blotting with an anti-
body that recognizes all forms of CD44 (5G8) or for erbB3 ex-
pression. Equal protein loading was confirmed by staining blots
with Ponceau S before probing with antibodies. CD44 expression
was not altered by the SAS oligonucleotide, but was reduced by
40–70% in AS oligonucleotide–treated cultures, as determined
by scanning densitometry. Treatment with AS1 and AS2 CD44
oligonucleotides did not influence erbB3 expression at 24 h. Treat-
ment with AS1 did result in a slight reduction in erbB3 expres-
sion (20–30%) after 36 h. This reduced expression probably was
due to increased levels of Schwann cell apoptosis in these cul-
tures (see below). (B and C) Schwann cell–neuron cocultures
were treated with 5 mM SAS (B) or 5 mM AS (C) oligonucle-
otides for 48 h. Cultures treated with SAS oligonucleotides dem-
onstrated numerous Schwann cells adhering to neurites (B, ar-
rows). Cultures treated with the AS oligonucleotide lacked Schwann
cells attached to neurites, demonstrating only naked neurites.
Clumps of dead cells were observed in these cultures (C, arrow). 
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(Fig. 8 B). These experiments were performed three times
with identical results, and indicate that lowering CD44 ex-
pression in Schwann cells significantly interferes with
erbB2–erbB3 heterodimerization and signaling in re-
sponse to neuregulins.
 
Discussion
 
We have demonstrated a novel role for CD44 in mediating
neuregulin signaling in Schwann cells. A number of previ-
ous studies established the importance of GGF and re-
lated neuregulins in promoting the survival of embryonic
Figure 6. Antisense CD44 induces Schwann cell rounding and death. Primary rat Schwann cells were grown in N2 in the presence of 5
ng/ml (A, B, and C) or 50 ng/ml (D, E, and F) rh-GGF2, then treated with AS1 (C and F), AS2 (C, inset), SAS1 (B and E), or SAS2 (B,
inset) oligonucleotides, or left untreated (A, D). After 48 h, SAS oligonucleotide–treated cultures were unaltered compared with un-
treated controls (compare A with B, D with E). Schwann cells grown in 5 ng/ml rh-GGF2 and treated with AS CD44 rounded up and
died within 48 h (compare B with C). This effect was partly reversed in cultures grown in the presence of 50 ng/ml rh-GGF2 (compare E
with F).
Figure 7. Antisense CD44 in-
duces Schwann cell apopto-
sis. Primary rat Schwann cells
were grown in the presence
of SAS (A) or AS (B) oligo-
nucleotides, then assayed at
24 h for apoptosis using a
DNA fragmentation detection
assay. Cells stained green with
counterstain alone were via-
ble, whereas cells with brown
nuclei had significant DNA
fragmentation. SAS-treated
cells demonstrated little de-
tectable DNA fragmentation
(A), whereas 20–30% of cells
treated with the AS oligonu-
cleotide demonstrated frag-
mentation. A higher percent-
age of cells may have had
DNA fragmentation, since
many of the AS-treated cells
lifted off the dish during the
course of the fragmentation
assay (B). 
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and early neonatal Schwann cells. Here, we demonstrated
that CD44 is also crucial for neonatal Schwann cell sur-
vival in vitro, that CD44 is constitutively associated with
erbB2 and erbB3 in Schwann cells, and that CD44 is re-
quired for erbB2–erbB3 heterodimerization in the pres-
ence of rh-GGF2. Lowering CD44 expression resulted in
loss of Schwann cell–neurite adhesion and Schwann cell
apoptosis, an effect that could be partially rescued by ex-
cess rh-GGF2. These data are consistent with neuregulins
being crucial for maintaining Schwann cell survival in vitro
and in situ (Grinspan et al., 1996; Syroid et al., 1996; Trach-
tenberg and Thompson, 1996; Kopp et al., 1997), and
show for the first time that interactions between CD44
and a growth factor receptor can enhance growth factor
signaling.
 
CD44 Facilitates Neuregulin Signaling through
erbB Receptors
 
erbB2 is the preferred heterodimerization partner of the
other erbB receptors (Graus-Porta et al., 1997). However,
it is unclear how erbB2 specifically associates with erbB1,
erbB3, or erbB4 in the presence of particular ligands. Our
data are consistent with the notion that CD44 plays a criti-
cal accessory role in bringing erbB2 and erbB3 together in
Schwann cells to form heterodimers in the presence of GGF.
It is possible that CD44 achieves this function by binding
GGF or other neuregulins, forming a ligand bridge be-
tween erbB2 and erbB3 that facilitates receptor interac-
tions. CD44 splice variants containing sequences encoded
by exon v3 can bind and sequester heparin binding growth
factors and present these growth factors to their high affin-
ity receptors (Brown et al., 1991; Faassen et al., 1992;
Tanaka et al., 1993; Bennett et al., 1995; Jackson et al.,
1995; Sherman et al., 1998; van der Voort et al., 1999). This
function of CD44 depends on heparin sulfate modifica-
tions to amino acids within the v3 variant sequence. Cer-
tain neuregulins, including GGF2, are heparin binding
growth factors (Ratner et al., 1988; Peles et al., 1993;
Sudhalter et al., 1996). Furthermore, heparin sulfate pro-
teoglycans on the surface of Schwann cells are required for
neuregulin signaling (Sudhalter et al., 1996; Loeb et al.,
1999). Heparin-binding neuregulins therefore could act to
bridge CD44–erbB2 and CD44–erbB3 complexes, result-
ing in a functional signaling receptor heterodimer (Fig. 9).
Although Schwann cells express CD44v3 variants at low
levels (Sherman et al., 1997), the majority of the CD44
that coimmunoprecipitated with erbB2 and erbB3 in
Schwann cells was the 85–95-kD standard CD44 protein
that lacks variant sequences. Therefore, it is possible that
CD44 contributes to erbB2–erbB3 heterodimerization
through a mechanism that does not depend on CD44–
GGF interactions via heparin sulfate. For example, CD44
may stabilize erbB2–erbB3 heterodimers through its inter-
actions with the actin cytoskeleton, either via ankyrin, an-
nexin II, or binding to members of the ezrin–radixin–
moesin family of actin-binding proteins (Kalomiris and
Bourguignon, 1989; Tsukita et al., 1994; Oliferenko et al.,
1999). We are presently performing experiments that will
distinguish between these possibilities.
Our data indicate that CD44 facilitates Schwann cell
erbB2–erbB3 heterodimerization and signaling in re-
sponse to a neuregulin. However, we cannot rule out the
possibility that CD44 has additional functions in Schwann
cells, including mediating signaling by other growth fac-
tors, cell-–cell adhesion, or cell–matrix interactions. For
example, Bourguignon et al. (1997) found that hyalur-
onate binding to CD44 could stimulate erbB2 phosphory-
lation in an ovarian carcinoma cell line. Hyaluronate could
cross-link CD44–erbB2 complexes with other erbB family
members also bound to CD44, resulting in erbB2 phos-
phorylation, or hyaluronate could stimulate cell signaling
through CD44, directly influencing erbB2 activity. The rel-
evance of these findings to Schwann cell biology remains
to be determined.
CD44 binds a number of extracellular matrix compo-
nents in addition to hyaluronate and may cooperate with
integrins to mediate cell adhesion (Fujisaki et al., 1999;
Figure 8. CD44 is required for erbB2 phosphorylation and
erbB2–erbB3 heterodimerization. (A) Schwann cells were grown
in the presence of 5 ng/ml rh-GGF2 and either 5 mM CD44 SAS1
(lane 1), 1 mM AS1 CD44 (lane 2), 5 mM AS1 (lane 3), 5 mM
SAS2 (lane 4), 1 mM AS2 (lane 5), or 5 mM AS2 (lane 6) for 24 h.
20 mg of protein were then separated by SDS-PAGE and ana-
lyzed by Western blotting for levels of CD44, erbB2, or phos-
phorylated erbB2 using a phospho-specific erbB2 antibody.
Equal protein loading was confirmed by Ponceau S staining.
ErbB2 phosphorylation was significantly reduced in the presence
of 1 mM AS1 (lane 2) and nearly absent in the presence of 5 mM
AS1 (lane 3), where CD44 expression was reduced by z50%.
Similar results were observed using AS2 (compare lanes 4, 5, and
6). Total erbB2 expression in cultures treated with 5 mM AS2 was
unchanged compared with controls and was reduced z25% in
cells treated with 5 mM AS1, probably due to increased levels of
Schwann cell apoptosis. These data indicate that reducing CD44
expression by Schwann cells inhibits erbB2 activation. (B)
Schwann cells grown in N2 alone were cultured in the presence of
either 5 mM SAS 1 or AS1 oligonucleotides for 24 h, then with 5
ng/ml of rh-GGF2 for 30 min. Total cell lysates were immunopre-
cipitated with an erbB2 antibody, then probed with an erbB3 an-
tibody. In this experiment, the total levels of erbB3 were not sig-
nificantly different between AS- and SAS-treated cultures.
However, erbB2 and erbB3 did not associate with one another in
cultures treated with AS CD44. These data indicate that CD44 is
required for erbB2-erbB3 heterodimerization. Lys, lysate; ip, im-
munoprecipitation with an erbB2 antibody. 
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Katagiri et al., 1999). Numerous studies have implicated
integrins and components of extracellular matrix in Schwann
cell survival, differentiation and growth (for review see
Mirsky and Jessen, 1999). Our own preliminary studies in-
dicate that Schwann cell apoptosis due to reduced CD44
expression is diminished when the cells are cultured on
laminin instead of poly-
 
L
 
-lysine (our unpublished observa-
tions). The finding that CD44 is expressed at the abaxonal
Schwann cell surface in adult myelinated nerves also
suggests a role for CD44 in mediating Schwann cell inter-
actions with components of the basal lamina that they
themselves synthesize (for review see Bunge, 1993). Fur-
thermore, studies of a transient population of CD44-posi-
tive cells in the developing mouse optic chiasm suggested
that CD44 may influence the function of the L1 cell adhe-
sion molecule (Sretavan et al., 1994) that has been impli-
cated in Schwann cell–axon adhesion in the peripheral
nervous system (Seilheimer and Schachner, 1988; Bixby
et al., 1988; Haney et al., 1999). CD44 proteins therefore
may function both in the mediation of neuregulin signaling
and in Schwann cell–axon adhesion, accounting for the
dramatic effects of CD44 antisense oligonucleotides in
Schwann cell–neuron cocultures.
If CD44 is critical for erbB2–erbB3 heterodimerization
and signaling, then one might predict that mice with tar-
geted mutations in the CD44 gene would have at least
some common phenotypes with mice lacking neuregulins,
erbB2, or erbB3. However, mice with targeted mutations
of the CD44 gene demonstrate only minor hematological
abnormalities that include aberrant lymphocyte recircula-
tion (Schmits et al., 1997; Protin et al., 1999). However,
mice with such targeted mutations can compensate for the
lack of one gene by upregulating the expression of related
genes. For example, mice with targeted mutations in the
cardiac alpha actin gene dramatically upregulate expres-
sion of vascular smooth muscle actin and skeletal alpha-
actins (Kumar et al., 1997). Therefore, it is possible that
embryos lacking CD44 from very early stages compensate
for the lack of CD44. In agreement with this notion, trans-
genic mice expressing antisense CD44 under the control of
the keratin-5-sulfate promoter have a dramatic skin phe-
notype, and keratinocytes from these animals fail to re-
spond properly to particular growth factors (Kaya et al.,
1997).
An alternative explanation for the phenotypic discrep-
ancy between mice with targeted 
 
CD44
 
 mutations and
findings from studies, including this one, where CD44 was
targeted with antisense strategies, is that additional gene
Figure 9. Two models of how CD44 could
function in erbB2–erbB3 heterodimerization
and signaling in Schwann cells. Our data indi-
cate that CD44 is constitutively associated
(either directly or indirectly) with erbB2 and
erbB3 in Schwann cells, and that CD44–
erbB2 and CD44–erbB3 complexes come to-
gether in the presence of GGF. ErbB3, which
has no intrinsic kinase activity (as denoted by
the white 3), can bind GGF, but erbB2,
which has kinase activity, cannot bind GGF
(left side of top and bottom models). Certain
CD44 proteins can bind heparin binding
growth factors, like GGF, either directly
through heparin sulfate–modified amino acid
sequences, or indirectly through an invariant
glycosaminoglycan binding domain that can
bind heparin sulfate. One possibility, there-
fore, is that CD44 facilitates erbB2–erbB3
heterodimerization by acting as a low affinity
receptor, anchoring GGF to the het-
erodimeric complex (top model). Another pos-
sibility, however, is that CD44 stabilizes
erbB2–erbB3 heterodimers through its inter-
actions with the actin cytoskeleton (bottom
model). The cytoplasmic tail of CD44 binds
to ezrin, radixin, and moesin (ERM proteins),
ankyrin, and annexin II, each of which associ-
ate with actin. Our data do not yet allow us to
distinguish between these two models. 
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transcripts are affected by antisense CD44. In the case of
our study, we cannot exclude this explanation. However,
several lines of evidence are consistent with CD44 being
linked to the observed effects of the oligonucleotides: (i)
the oligonucleotide sequences we used previously have been
shown to specifically reduce CD44 expression in rat cells
and to cause phenotypes that were predicted from inde-
pendent, biochemical data (Lamb et al., 1997); (ii) the oli-
gonucleotide sequences we used do not share homology with
other known genes, including the recently cloned CD44
homologue LYVE-1 (Banerji et al., 1999); (iii) the effects
of antisense CD44 on Schwann cells are consistent with
our findings that CD44 colocalizes and interacts with
erbB2 and erbB3; and (iv) antisense strategies have been
used successfully to reduce CD44 in a number of in vitro
and in vivo systems, often resulting in phenotypes that
were predicted by independent means (Merzak et al., 1994;
Lamb et al., 1997; Kaya et al., 1997, 1999; Chow et al.,
1998; Reeder et al., 1998).
 
CD44 May Be Required for Other Processes Linked to 
erbB Receptor Signaling
 
The observation that CD44 expression is highest in early
postnatal peripheral nerves at times when Schwann cells
are proliferating and then declines as Schwann cells be-
come quiescent is consistent with the idea that CD44–
erbB2/erbB3 interactions mediate Schwann cell prolif-
eration during peripheral nerve development. CD44 may
also play a role in conditions characterized by abnormal
Schwann cell proliferation, such as Wallerian degeneration
and Schwann cell tumorigenesis. Interestingly, 
 
NRG-1
 
 tran-
scripts, including GGF mRNAs, are induced in adult nerves
during Wallerian degeneration (Carroll et al., 1997), and
Schwann cells themselves produce neuregulins (Raabe et al.,
1996; Rosenbaum et al., 1997; Cheng et al., 1998), suggest-
ing that CD44 could be involved in a neuregulin autocrine
signaling loop under certain circumstances. Furthermore,
we found elevated CD44 expression in schwannomas with
mutations in the 
 
NF2
 
 gene (Sherman et al., 1997), whose
protein product, merlin, associates with the cytoplasmic
tail of CD44 (Sainio et al., 1997). Some of the abnormal
growth and survival properties of schwannoma cells are
consistent with aberrant cell adhesion and growth and sur-
vival signaling (Pelton et al., 1998; Rosenbaum et al.,
1998). Therefore, it is intriguing to speculate that CD44–
erbB receptor interactions contribute to Schwann cell tu-
morigenesis and other peripheral nerve pathologies.
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